The PARP Inhibitor Cancer Therapy Market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Key players’ focus on research and development to develop new products is anticipated to drive the market. For example, in May 2020, the Food and Drug Administration approved the poly ADP-ribose polymerase (PARP) inhibitor monotherapy niraparib […]
